Neurocrine Biosciences, Inc. (BIT:1NBIX)

Market Cap	11.53B -19.3%
Revenue (ttm)	2.29B +19.6%
Net Income	364.78M +10.9%
EPS	3.57 +12.4%
Shares Out	n/a
PE Ratio	31.62
Forward PE	14.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	119.75
Previous Close	119.75
Day's Range	119.75 - 119.75
52-Week Range	92.16 - 145.95
Beta	n/a
RSI	50.46
Earnings Date	Feb 11, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1NBIX

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD